|
시장보고서
상품코드
2075136
경구 생물제제 시장 : 약제 클래스별, 질환 적응별, 유통 채널별, 지역별Oral Biologics Market, By Drug Class, By Disease Indication, By Distribution channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
경구 바이오의약품 시장은 2026년에 65억 2,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 549억 8,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 35.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 65억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 35.60% | 2033년 시장 규모 예측 : | 549억 8,000만 달러 |
생물제제란 생물 유래이거나 생물의 성분을 포함하는 치료용 제품을 말합니다. 생물제제는 당뇨병, 일반 건선, 관절염, 크론병, 궤양성 대장염 등 수많은 질환의 치료에 널리 사용되고 있습니다.
경구용 생물제제란, 구강 질환의 적응증에 대해 복용되는 생물제제를 말합니다. 현재 생물제제의 대부분은 비경구 투여 방식으로 투여되고 있으며, 시중에 승인된 경구용 생물제제는 구아닐레이트 시클라제-C 작용제 계열의 약물뿐입니다.
그러나 시장의 주요 기업은 다양한 적응증을 대상으로 하는 경구 투여형 글루카곤 유사 펩티드-1(GLP-1) 수용체 작용제, 재조합 효소, 소마토스타틴 유사체 및 각종 호르몬의 개발에 주력하고 있습니다.
시장 역학
주요 기업의 제휴, 파트너십, 합병, 인수와 같은 비유기적 전략의 증가는 시장 성장을 이끄는 주요 요인이 되고 있습니다. 예를 들어 2021년 2월, Biocon Limited는 인슐린 바이오시밀러 기업인 International Diabetes Federation(IDF)과의 합병을 발표했습니다. 이번 합병은 Biocon의 바이오의약품 부문 연구개발에 중점을 두고, Biocon이 제조하는 인슐린 제품을 전 세계 당뇨병 환자들이 합리적인 가격에 이용할 수 있도록 하는 것을 목표로 하고 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 경구용 생물제제 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 시장내 입지, 유통 전략, 주요 발전 사항, 전략 및 향후 계획입니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 경구용 바이오의약품 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 경구용 바이오의약품 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 경구 생물제제 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 경구 생물제제 시장 : 질환 적응증별, 2021-2033년
제6장 세계의 경구 생물제제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 경구 생물제제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.07.07Oral Biologics Market is estimated to be valued at USD 6.52 Bn in 2026 and is expected to reach USD 54.98 Bn by 2033, growing at a compound annual growth rate (CAGR) of 35.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6.52 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 35.60% | 2033 Value Projection: | USD 54.98 Bn |
Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn's disease, and ulcerative colitis.
Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.
However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.
Market Dynamics
Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon's biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global oral biologics market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market
Detailed Segmentation:
- Global Oral Biologics Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
- Global Oral Biologics Market, By Disease Indication (Revenue, USD Bn, 2021 - 2033)
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- Global Oral Biologics Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Oral Biologics Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- By Drug Class
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
- By Disease Indication
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- By Drug Class
- Latin America
- By Drug Class
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
- By Disease Indication
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class
- Europe
- By Drug Class
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
- By Disease Indication
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Drug Class
- Asia Pacific
- By Drug Class
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
- By Disease Indication
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drug Class
- Middle East
- By Drug Class
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
- By Disease Indication
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- By Drug Class
- Africa
- By Drug Class
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
- By Disease Indication
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
- By Drug Class
- Company Profiles
- Novo Nordisk A/S *
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biocon Limited
- Oramed Pharmaceuticals, Inc.
- Rani Therapeutics
- Entera Bio Ltd.
- AbbVie Inc.
- Enteris BioPharma, Inc.
- Chiasma, Inc.
- Allena Pharmaceuticals, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Oral Biologics Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Recombinant Enzyme
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Guanylate Cyclase-C Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Somatostatin Analogue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
5. Global Oral Biologics Market, By Disease Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Hyperoxaluria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Acromegaly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
6. Global Oral Biologics Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Oral Biologics Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 - 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Novo Nordisk A/S
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Biocon Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Oramed Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Rani Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Entera Bio Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Enteris BioPharma, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Chiasma, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Allena Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novo Nordisk A/S
9. Section
- References
- Research Methodology
- About us and Sales Contact
